GenScript Biotech Achieves EcoVadis Bronze Medal for Sustainability Excellence in 2025
GenScript Biotech Corporation has recently made headlines as it was presented with the EcoVadis Bronze Medal for the second consecutive year. This honor not only underscores GenScript's dedication to sustainability but also highlights its prominence as a leader in the life sciences sector. With a notable ranking within the top 10% of companies assessed in the basic pharmaceutical products and preparations industry, GenScript managed to outperform over 83% of all companies evaluated by EcoVadis.
Sustainability is becoming increasingly important in today's business landscape, and GenScript’s achievements reflect its steadfast commitment to responsible corporate practices. Sherry Shao, the Rotating CEO of GenScript, expressed pride in receiving this accolade again, emphasizing that sustainability is an integral part of their mission. Over the past year, the company has worked diligently to optimize operations, aiming to reduce their environmental impact while promoting ethical practices and fostering social responsibility. This focus on sustainability is not merely a short-term goal but rather a long-term strategy that GenScript aims to build upon in collaboration with its global partners.
EcoVadis is recognized worldwide for its comprehensive sustainability ratings, which are based on standards such as the Global Reporting Initiative (GRI), the United Nations Global Compact (UNGC), and ISO 26000. These assessments encompass various metrics, including environmental impact, labor and human rights, business ethics, and sustainable procurement. The fact that GenScript is ranked in a prestigious position cements its reputation as a trusted partner within the healthcare and life sciences ecosystem.
In addition to the EcoVadis recognition, GenScript's sustainability initiatives have garnered further international acclaim. In 2023, the company joined the United Nations Global Compact, adhering to principles regarding human rights, labor, and environmental stewardship. The following year, GenScript and its subsidiary, ProBio, solidified their sustainability commitment by partnering with the Pharmaceutical Supply Chain Initiative (PSCI), supporting a more sustainable and ethical pharmaceutical industry.
On the financial side, GenScript has witnessed significant improvements in its ESG (Environmental, Social, and Governance) efforts, as evidenced by an upgrade in its MSCI ESG rating from BBB to A. This rating reflects the company's robust performance in environmental sustainability and social responsibility. Additionally, GenScript's ambitious carbon reduction targets have recently received validation from the Science Based Targets Initiative (SBTi), marking a crucial milestone in their commitment to global decarbonization.
Looking to the future, GenScript remains relentless in its mission to embed sustainability within its core operations. The company believes that innovation and collaboration are key to enhancing the overall health of society and the planet. This vision supports their strategy to ensure that sustainability is not just a checkbox but an ingrained aspect of how they operate across all facets of the business.
Founded in 2002 in New Jersey, GenScript has been at the forefront of life sciences research. The company is dedicated to advancing innovation in healthcare and consumer goods by providing researchers and businesses with the foundational tools necessary for developing groundbreaking solutions. Currently, GenScript boasts a workforce of over 5,500 employees, having served more than 200,000 clients across more than 100 countries. With a focus on making people and nature healthier through biotechnology, GenScript continues to position itself as a global leader dedicated to sustainable progress in the life sciences realm.
Sustainability is becoming increasingly important in today's business landscape, and GenScript’s achievements reflect its steadfast commitment to responsible corporate practices. Sherry Shao, the Rotating CEO of GenScript, expressed pride in receiving this accolade again, emphasizing that sustainability is an integral part of their mission. Over the past year, the company has worked diligently to optimize operations, aiming to reduce their environmental impact while promoting ethical practices and fostering social responsibility. This focus on sustainability is not merely a short-term goal but rather a long-term strategy that GenScript aims to build upon in collaboration with its global partners.
EcoVadis is recognized worldwide for its comprehensive sustainability ratings, which are based on standards such as the Global Reporting Initiative (GRI), the United Nations Global Compact (UNGC), and ISO 26000. These assessments encompass various metrics, including environmental impact, labor and human rights, business ethics, and sustainable procurement. The fact that GenScript is ranked in a prestigious position cements its reputation as a trusted partner within the healthcare and life sciences ecosystem.
In addition to the EcoVadis recognition, GenScript's sustainability initiatives have garnered further international acclaim. In 2023, the company joined the United Nations Global Compact, adhering to principles regarding human rights, labor, and environmental stewardship. The following year, GenScript and its subsidiary, ProBio, solidified their sustainability commitment by partnering with the Pharmaceutical Supply Chain Initiative (PSCI), supporting a more sustainable and ethical pharmaceutical industry.
On the financial side, GenScript has witnessed significant improvements in its ESG (Environmental, Social, and Governance) efforts, as evidenced by an upgrade in its MSCI ESG rating from BBB to A. This rating reflects the company's robust performance in environmental sustainability and social responsibility. Additionally, GenScript's ambitious carbon reduction targets have recently received validation from the Science Based Targets Initiative (SBTi), marking a crucial milestone in their commitment to global decarbonization.
Looking to the future, GenScript remains relentless in its mission to embed sustainability within its core operations. The company believes that innovation and collaboration are key to enhancing the overall health of society and the planet. This vision supports their strategy to ensure that sustainability is not just a checkbox but an ingrained aspect of how they operate across all facets of the business.
Founded in 2002 in New Jersey, GenScript has been at the forefront of life sciences research. The company is dedicated to advancing innovation in healthcare and consumer goods by providing researchers and businesses with the foundational tools necessary for developing groundbreaking solutions. Currently, GenScript boasts a workforce of over 5,500 employees, having served more than 200,000 clients across more than 100 countries. With a focus on making people and nature healthier through biotechnology, GenScript continues to position itself as a global leader dedicated to sustainable progress in the life sciences realm.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.